New manual drafted by psychiatrists with ties to drug industry
But conflicts of interest will be eliminated
More than half of 28 new contributors to the next edition of the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM) have ties to the drug industry, according to the website Integrity in Science, a project of the Center for Science in the Public Interest. The DSM is used by mental health professionals to classify mental illnesses.
The conflicts of interests, which ranged from small to extensive, have been posted online by the Association. One member has worked as a consultant for 13 drug companies, over the past last five years, including Pfizer, Eli Lilly, Wyeth, Merck, Astra Zeneca, and Bristol-Myers Squibb. However, the Association’s president, Carolyn B. Robinowitz, claimed that "we have made every effort to ensure that DSM-V will be based on the best and latest scientific research, and to eliminate conflicts of interest in its development." The consultants have agreed not to allow their annual income from industry sources to exceed US$10,000 while they are working on the report. ~ Integrity in Science Watch, May 5
- How long can you put off seeing the doctor because of lockdowns? - December 3, 2021
- House of Lords debates assisted suicide—again - October 28, 2021
- Spanish government tries to restrict conscientious objection - October 28, 2021
More Stories
Mortality rates for American kids are rising for the first time in 50 years
US President Joe Biden is so concerned about the future of American children that he inserted a mandate for affordable...
Will Pope Francis be composted?
Will Pope Francis be composted instead of buried in St Peter’s Basilica in Rome with his predecessors? It’s unlikely. But...
The virtues and the vices of the outrageous
A Norwegian bioethicist, Anna Smajdor, recently set out a case for “Whole Body Gestational Donation” – using the wombs of...
More than 200 people have been treated with experimental CRISPR therapies
Scientists believe that CRISPR gene editing technologies will transform medicine. But how many people have been treated so far? According...
Asia-Pacific IVF market could reach US$46 billion by 2031
According to a market survey by Allied Market Research, IVF is booming in the Asia-Pacific region. The market size was...
Third global summit on human genome editing: Moving on after the He experiment
The much anticipated Third International Summit on Human Genome Editing was held in London earlier this month to explore the...